Opinion: Pfizer's Dividend Riskier Than It Looks, Even with a 7% Yield
Pfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
Timing profit-taking in retirement rebalancing helps lock in gains while preserving the plan. This guide highlights practical timing cues and rules.
17,033 articlesPfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
A high-profile insider sale at CoreWeave has sparked questions about the company’s trajectory. This guide explains wh...
Standard Chartered challenges the de-dollarization narrative, arguing that global focus remains on the U.S. dollar as...
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
A modest Tuesday gain for SPGI helped the stock beat the broad market's small rise. This piece explains what a global...
International stocks winning again is moving from headlines to portfolio reality as ex-US ETFs post strong gains and ...
Nvidia stands at a crossroads as it prepares to report Feb earnings. This article unpacks why the result could redefi...
For investors who want AI-driven growth without oversized risk, Nvidia offers a compelling path. This guide shows how...
A universal technical institute director recently sold 10,000 shares, sparking questions about what it means for UTI ...
Friday marks the first triple witching of 2026 as Iran tensions flare, prompting investors to brace for volatile move...
Fears about a recession can shake even seasoned investors. This article unpacks this warren buffett's golden rule and...
The Stanford board sold HeartFlow shares for about $8.5 million, triggering questions about insider signals. This art...